The cyclic AMP pathway is a sex-specific modifier of glioma risk in type I neurofibromatosis patients

Cancer Research

Volumn 75, Issue 1, 2015, Pages 16-21

  Warrington, Nicole M ^a   Sun, Tao ^a   Luo, Jingqin ^a   McKinstry, Robert C ^a,b   Parkin, Patricia C ^c   Ganzhorn, Sara ^a   Spoljaric, Debra ^a   Albers, Anne C ^a   Merkelson, Amanda ^d   Stewart, Douglas R ^e   Stevenson, David A ^f   Viskochil, David ^g   Druley, Todd E ^a   Forys, Jason T ^a   Reilly, Karlyne M ^e   Fisher, Michael J ^h,i   Tabori, Uri ^c   Allen, Jeffrey C ^d   Schiffman, Joshua D ^f   Gutmann, David H ^a   Rubin, Joshua B ^a   more..

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c HOSPITAL FOR SICK CHILDREN   (Canada)

^d NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

^e NATIONAL CANCER INSTITUTE   (United States)

^f UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^g UNIVERSITY OF UTAH   (United States)

^h CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

ⁱ UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIC AMP;

ADENYLATE CYCLASE 8 GENE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ASTROCYTE; CANCER RISK; CARCINOGENESIS; CONTROLLED STUDY; FEMALE; GENETIC ASSOCIATION; GLIOMA; HIGH RISK PATIENT; MALE; MOUSE; NEUROFIBROMATOSIS; NEWBORN; NONHUMAN; ONCOGENE; PROTEIN EXPRESSION; REGULATORY MECHANISM; RISK ASSESSMENT; RISK REDUCTION; SENSITIVITY ANALYSIS; SEX DIFFERENCE; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; ANIMAL; C57BL MOUSE; GENETICS; HUMAN; METABOLISM; NEUROFIBROMATOSIS TYPE 1; PATHOLOGY; RISK FACTOR;

ANIMALS; ASTROCYTES; CYCLIC AMP; FEMALE; GLIOMA; HUMANS; MALE; MICE; MICE, INBRED C57BL; NEUROFIBROMATOSIS 1; RISK FACTORS; SEX FACTORS; SIGNAL TRANSDUCTION;

EID: 84920540572     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-14-1891     Document Type: Article

References (29)

1. Rubin JB, Gutmann DH. Neurofibromatosis type I - a model for nervous system tumour formation? Nat Cancer Rev 2005;5:557-64.
2. Ferner RE, Huson SM, Thomas N, Moss C, Willshaw H, Evans DG, et al. Guidelines for the diagnosis and management of individuals with neurofibromatosis 1. J Med Genet 2007;44:81-8.
3. Listernick R, Ferner RE, Liu GT, Gutmann DH. Optic pathway gliomas in neurofibromatosis-1: controversies and recommendations. Ann Neurol 2007;61:189-98.
4. Nicolin G, Parkin P, Mabbott D, Hargrave D, Bartels U, Tabori U, et al. Natural history and outcome of optic pathway gliomas in children. Pediatr Blood Cancer 2009;53:1231-7.
5. Warrington NM, Woerner BM, Daginakatte GC, Dasgupta B, Perry A, Gutmann DH, et al. Spatiotemporal differences in CXCL12 expression and cyclic AMP underlie the unique pattern of optic glioma growth in neurofibromatosis type 1. Cancer Res 2007;67:8588-95.
6. Bajenaru ML, Hernandez MR, Perry A, Zhu Y, Parada LF, Garbow JR, et al. Optic nerve glioma in mice requires astrocyte Nf1 gene inactivation and Nf1 brain heterozygosity. Cancer Res 2003;63:8573-7.
7. Warrington NM, Gianino SM, Jackson E, Goldhoff P, Garbow JR, Piwnica-Worms D, et al. Cyclic AMP supppression is sufficient to induce gliomagenesis in a mouse model of Neurofibromatosis-1. Cancer Res 2010;70:5717-27.
8. Ji J, Shimony J, Gao F, McKinstry RC, Gutmann DH. Optic nerve tortuosity in children with neurofibromatosis type 1. Pediatr Radiol 2013;43:1336-43.
9. Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MA, Bender D, et al. PLINK: a tool set for whole-genome association and population-based linkage analyses. Am J Hum Genet 2007;81:559-75.
10. Zheng X, Levine D, Shen J, Gogarten SM, Laurie C, Weir BS. A high-performance computing toolset for relatedness and principal component analysis of SNP data. Bioinformatics 2012;28:3326-8.
11. Gogarten SM, Bhangale T, Conomos MP, Laurie CA, McHugh CP, Painter I, et al. GWASTools: an R/Bioconductor package for quality control and analysis of genome-wide association studies. Bioinformatics 2012;28:3329-31.
12. Amigo J, Salas A, Phillips C. ENGINES: exploring single nucleotide variation in entire human genomes. BMC Bioinformatics 2011;12:105.
13. Diggs-Andrews KA, Brown JA, Gianino SM, Rubin JB, Wozniak DF, Gutmann DH. Sex is a major determinant of neuronal dysfunction in neurofibromatosis type 1. Ann Neurol 2014;75:309-16.
14. Xu J, Deng X, Disteche CM. Sex-specific expression of the X-linked histone demethylase gene Jarid1c in brain. PLoS One 2008;3:e2553.
15. Ober C, Loisel DA, Gilad Y. Sex-specific genetic architecture of human disease. Nat Rev Genet 2008;9:911-22.
16. Amlin-Van Schaick JC, Kim S, DiFabio C, Lee MH, Broman KW, Reilly KM. Arlm1 is a male-specific modifier of astrocytoma resistance on mouse Chr 12. Neuro Oncol 2012;14:160-74.
17. Walrath JC, Fox K, Truffer E, Gregory Alvord W, Quinones OA, Reilly KM. Chr 19(A/J) modifies tumor resistance in a sex- and parent-of-origin-specific manner. Mamm Genome 2009;20:214-23.
18. Taylor MD, Northcott PA, Korshunov A, Remke M, Cho YJ, Clifford SC, et al. Molecular subgroups of medulloblastoma: the current consensus. Acta Neuropathol 2012;123:465-72.
19. Listernick R, Darling C, Greenwald M, Strauss L, Charrow J. Optic pathway tumors in children: the effect of neurofibromatosis type 1 on clinical manifestations and natural history. J Pediatr 1995;127:718-22.
20. Chateil JF, Soussotte C, Pedespan JM, Brun M, Le Manh C, Diard F. MRI and clinical differences between optic pathway tumours in children with and without neurofibromatosis. Br J Radiol 2001;74:24-31.
21. Czyzyk E, Jozwiak S, Roszkowski M, Schwartz RA. Optic pathway gliomas in children with and without neurofibromatosis 1. J Child Neurol 2003;18:471-8.
22. Thiagalingam S, Flaherty M, Billson F, North K. Neurofibromatosis type 1 and optic pathway gliomas: follow-up of 54 patients. Ophthalmology 2004;111:568-77.
23. Blazo MA, Lewis RA, Chintagumpala MM, Frazier M, McCluggage C, Plon SE. Outcomes of systematic screening for optic pathway tumors in children with Neurofibromatosis Type 1. Am J Med Genet 2004;127A:224-9.
24. Pascual-Castroviejo I, Pascual-Pascual SI, Velazquez-Fragua R, Viano J, Garcia-Segura JM, Botella MP. [Neurofibromatosis type 1 and optic pathway gliomas.A series of 80 patients]. Revista de neurologia 2008;46:530-6.
25. Segal L, Darvish-Zargar M, Dilenge ME, Ortenberg J, Polomeno RC. Optic pathway gliomas in patients with neurofibromatosis type 1: follow-up of 44 patients. J AAPOS 2010;14:155-8.
26. de Blank PM, Berman JI, Liu GT, Roberts TP, Fisher MJ. Fractional anisotropy of the optic radiations is associated with visual acuity loss in optic pathway gliomas of neuro fibromatosis type 1. Neuro Oncol 2013;15:1088-95.
27. Incecik F, Altunbasak S, Herguner MO, Bayram I, Kupeli S, Demirbilek H. Oncologic manifestations in children with neuro fibromatosis type 1 in Turkey. Tur J Pediatr 2013;55:266-70.
28. Goodden J, Pizer B, Pettorini B, Williams D, Blair J, Didi M, et al. The role of surgery in optic pathway/hypothalamic gliomas in children. J Neurosurg Pediatr 2014;13:1-12.
29. Kalin-Hajdu E, Decarie JC, Marzouki M, Carret AS, Ospina LH. Visual acuity of children treated with chemotherapy for optic pathway gliomas. Pediatr Blood Cancer 2014;61:223-7.